Compass Therapeutics (CMPX) shares were down nearly 7% on Wednesday after Wedbush downgraded the company's stock to neutral from outperform and cut the price target to $1 from $5.
Trading volume stood at more than 4.7 million shares against a daily average of around 3.3 million.
Price: $1.16, Change: $-0.09, Percent Change: -6.85%